The Drug Trial: Nancy Olivieri and the Science Scandal that Rocked the Hospital for Sick ChildrenBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7508.115 (Published 07 July 2005) Cite this as: BMJ 2005;331:115
- Christopher Martyn, associate editor (firstname.lastname@example.org)
The facts go something like this. In 1996 Nancy Olivieri, a haematologist working at the Hospital for Sick Children in Toronto, came to believe that an experimental iron chelating drug (deferiprone) that she was trialling in patients with thalassaemia was losing efficacy and causing serious adverse effects. Apotex, the company that made the drug and that was partly funding the trial, disagreed. When Olivieri indicated that she intended to inform participants of her concerns, Apotex terminated the trials and withdrew financial support. They invoked a confidentiality agreement in the research contract and threatened legal action if she made the findings public. Undeterred, Olivieri presented her results at a scientific meeting and submitted them for publication.
Shuchman retells the story from a worm's eye view, dwelling on the personalities involved, what they said about each other, who was sleeping with whom
Events after the dispute between Olivieri and Apotex showed deep divisions and personal …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial